Notifications
Back

Leadership

Three Co-Founders, 

Unrivaled Scientific Capability

In-San Kim

Co-Founder / MD, PhD
Founding Visionary and Principal Technologist

  • MD.PhD. from Kyungpook National University
  • KIST Fellow Researcher
  • Professor at KU-KIST Graduate School
  • Expertise in Immunology and NNP Therapy
  • Published over 400 papers (h-index: 90)

Gi-Hoon Nam

Co-Founder / MD, PhD
Chief Executive Officer

  • MD. from Korea University
  • PhD. from KU-KIST Graduate School
  • Professor at Korea University College of Medicine
  • Research on drug development at KIST and Harvard Medical School

Won-Yong Lee

Co-Founder / MD, PhD
Chief Executive Officer 

  • MD. from Seoul National University
  • PhD. from Sungkyunkwan University
  • Fellow at Seoul National University Hospital
  • Otolaryngologist at Samsung Medical Center
  • Professor at Busan National University

Meet the TEAM


Team SHIFTBIO is demonstrating the best teamwork for a common goal.


We respect the capabilities
that each individual can demonstrate

and the synergy effect created
through cooperation

More

For successful drug development
We are organizing the Scientific Advisory Board(SAB)
by consulting with authorities in each field
and discussing with renowned experts around the world

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies

Biomarker Research

Dolores Di Vizio, MD, PhD. 
  • Professor, Cedars-Sinai, Pathology and Laboratory Medicine 
  • Co-Leader, Cancer Biology Program, Cedars-Sinai, Cancer Institute 
  • Senior Advisor, International Society of Extracellular Vesicles

World-class scientist in circulating NNPs

For successful drug development
We are organizing the Scientific Advisory Board(SAB) by consulting with authorities in each field and discussing with renowned experts around the world

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies


Biomarker Research

Dolores Di Vizio, MD, PhD. 
  • Professor, Cedars-Sinai, Pathology and Laboratory Medicine 
  • Co-Leader, Cancer Biology Program, Cedars-Sinai, Cancer Institute 
  • Senior Advisor, International Society of Extracellular Vesicles 

World-class scientist in circulating NNPs